HIV-1 viral protein R compromises cellular immune function in vivo

International Immunology

Volumn 14, Issue 1, 2002, Pages 13-22

  Ayyavoo, Velpandi ^b   Muthumani, Karuppiah ^a   Kudchodkar, Sagar ^a   Zhang, Donghui ^a   Ramanathan, P ^a   Dayes, Nathanael S ^a   Kim, J J ^a   Sin, Jeong Im ^a   Montaner, Luis J ^c   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Antigen presenting cell; Antigen speific immune response; HIV 1 viral protein R; T cell activation; Th1 Th2 cytokine; Vaccination

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; VPR PROTEIN;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; BIOLOGICAL MODEL; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; IN VIVO STUDY; INFECTION RESISTANCE; INFLAMMATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS CELL INTERACTION; VIRUS VIRULENCE;

EID: 0036150615     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/14.1.13     Document Type: Article

References (55)

1. Antisence phosphorothiate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages
2. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
3. The human immunodeficiency virus type 1 vpr gene is essential for productive infection of human macrophages
4. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor κB
5. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor
6. Human immunodeficiency virus type-1 and cytomegalovirus specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4 T cells
7. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1
8. Extra cellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency
9. 2 + M phase of the cell cycle
10. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest
11. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells
12. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions
13. Incorporation of vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of gag and mutational analysis
14. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
15. + blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells
16. Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells
17. The macrophage scavenger receptor type A directs modified proteins to antigen presentation
18. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo
19. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
20. + lymphocytes
21. Development of genetic vaccine for pathogenic genes: Construction of attenuated vif DNA immunization cassettes
22. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine
23. Genetic immunization is a simple method for eliciting an immune response
24. DNA immunization: Effect of secretion of DNA-expressed hemagglutinins on antibody responses
25. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting
26. DNA-based immunization by in vivo transfection of dendritic cells
27. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells
28. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis
29. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial
30. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
31. HIV-1 Nef mediates lymphocyte chemotaxix and activation by infected macrophages
32. Essential role of phosphatidylserine externalization in apoptosing cell phagocytosis by macrophages
33. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
34. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr
35. A Vpr-GFP particle identifies infected targets and preserves HIV-1 Vpr function in macrophages and dendritic cells
36. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
37. + lymphocytes
38. Induction of cell differentiation by human immunodeficiency virus 1 vpr
39. CD86 (B7.2) can function to drive MHC-restricted antigen-specific CTL responses in vivo
40. Engineering of in vivo immune responses to DNA immunization via codelivery of constimulatory molecule genes
41. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
42. + T-cell mechanisms in the control of respiratory virus infections
43. + T cell responses associated with control of viremia
44. + memory T cells in an immunoprivileged site
45. + T cells. Evidence for a soluble inhibitor
46. + T cells
47. In vivo migration and function of transferred HIV-1 specific cytotoxic T cells
48. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
49. CD8 naive T cell counts decrease progressively in HIV-infected adults
50. + cell anti-HIV activity correlates with the clinical state of the infected individual
51. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors
52. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
53. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
54. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell